$GNPX
Genprex Inc

2024 Q2 Form 10-Q Financial Statement

#000143774924017061 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.849M $2.720M
YoY Change 19.74% -31.32%
% of Gross Profit
Research & Development $1.667M $3.274M
YoY Change -58.1% -38.34%
% of Gross Profit
Depreciation & Amortization $2.288K $2.670K
YoY Change -40.37% -33.52%
% of Gross Profit
Operating Expenses $1.667M $3.274M
YoY Change -58.1% -38.34%
Operating Profit -$6.518M -$5.997M
YoY Change -18.88% -35.32%
Interest Expense $22.44K $27.85K
YoY Change -62.6% -60.21%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.496M -$5.969M
YoY Change -18.6% -35.12%
Income Tax
% Of Pretax Income
Net Earnings -$6.496M -$5.969M
YoY Change -18.6% -35.14%
Net Earnings / Revenue
Basic Earnings Per Share -$3.00 -$3.69
Diluted Earnings Per Share -$3.01 -$3.69
COMMON SHARES
Basic Shares Outstanding 2.099M 1.910M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.459M $8.217M
YoY Change -75.3% -54.56%
Cash & Equivalents $2.459M $8.217M
Short-Term Investments
Other Short-Term Assets $1.936M $1.011M
YoY Change -19.69% -45.64%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables
Total Short-Term Assets $4.395M $9.228M
YoY Change -64.46% -53.73%
LONG-TERM ASSETS
Property, Plant & Equipment $1.735K $4.023K
YoY Change -88.57% -78.84%
Goodwill
YoY Change
Intangibles $0.00 $790.5K
YoY Change -100.0% 9.52%
Long-Term Investments
YoY Change
Other Assets $2.208M $3.333M
YoY Change -37.44% -0.78%
Total Long-Term Assets $2.210M $3.337M
YoY Change -37.66% -1.22%
TOTAL ASSETS
Total Short-Term Assets $4.395M $9.228M
Total Long-Term Assets $2.210M $3.337M
Total Assets $6.605M $12.56M
YoY Change -58.49% -46.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.175M $2.152M
YoY Change -21.57% -2.71%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.259M $3.808M
YoY Change -41.47% -21.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.259M $3.808M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $2.259M $3.808M
YoY Change -41.47% -21.25%
SHAREHOLDERS EQUITY
Retained Earnings -$146.2M -$139.7M
YoY Change 21.78% 24.66%
Common Stock $2.556K $1.923K
YoY Change -95.08% -96.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.346M $8.757M
YoY Change
Total Liabilities & Shareholders Equity $6.605M $12.56M
YoY Change -58.49% -46.12%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$6.496M -$5.969M
YoY Change -18.6% -35.14%
Depreciation, Depletion And Amortization $2.288K $2.670K
YoY Change -40.37% -33.52%
Cash From Operating Activities -$5.796M -$5.298M
YoY Change -28.51% -23.58%
INVESTING ACTIVITIES
Capital Expenditures -$17.00K $16.99K
YoY Change -185.0% -13.45%
Acquisitions
YoY Change
Other Investing Activities -$30.00 $1.170K
YoY Change
Cash From Investing Activities $16.97K -$15.82K
YoY Change -184.85% -19.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.76K $6.793M
YoY Change 66.47%
NET CHANGE
Cash From Operating Activities -5.796M -$5.298M
Cash From Investing Activities 16.97K -$15.82K
Cash From Financing Activities 20.76K $6.793M
Net Change In Cash -5.758M $1.479M
YoY Change -29.15% -151.53%
FREE CASH FLOW
Cash From Operating Activities -$5.796M -$5.298M
Capital Expenditures -$17.00K $16.99K
Free Cash Flow -$5.779M -$5.315M
YoY Change -28.89% -23.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1922586
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1922586
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1485902
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1485902
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5996717 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9264554 usd
CY2024Q1 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
135 usd
CY2023Q1 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-6691 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-5968869 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9202774 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.69
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.44
CY2024Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2023Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
57.79
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
172.81
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.93
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
89.56
CY2024Q1 gnpx Class Of Warrant Or Right Exercisable Exercise Price
ClassOfWarrantOrRightExercisableExercisePrice
5.8
CY2023Q1 gnpx Class Of Warrant Or Right Exercisable Exercise Price
ClassOfWarrantOrRightExercisableExercisePrice
59.79
CY2024Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
121.11
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
123.19
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
121.25
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
122.72
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
126.16
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
129.51
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-38244
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-0772347
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3300 Bee Cave Road, #650-227
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78746
CY2024Q1 dei City Area Code
CityAreaCode
512
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
537-7997
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
GNPX
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2098698
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8217115 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6737629 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1010761 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
794138 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
9227876 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
7531767 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4023 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7859 usd
CY2024Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
10000 usd
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
10000 usd
CY2024Q1 gnpx Research And Development Assets Noncurrent
ResearchAndDevelopmentAssetsNoncurrent
2532226 usd
CY2023Q4 gnpx Research And Development Assets Noncurrent
ResearchAndDevelopmentAssetsNoncurrent
2347488 usd
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
790466 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
773478 usd
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3332692 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3130966 usd
CY2024Q1 us-gaap Assets
Assets
12564591 usd
CY2023Q4 us-gaap Assets
Assets
10670592 usd
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2152210 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1397610 usd
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1655701 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1856598 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3807911 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3254208 usd
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
1923 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1486 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
148411906 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
141103178 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-139657149 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-133688280 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
8756680 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
7416384 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12564591 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10670592 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3274380 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5310148 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2719667 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3950390 usd
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
5996717 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
9264554 usd
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
27713 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
68471 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1618240
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1236822
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
7416384 usd
CY2024Q1 gnpx Stock And Warrants Issued During Period Value New Issues
StockAndWarrantsIssuedDuringPeriodValueNewIssues
6793199 usd
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
180720 usd
CY2024Q1 gnpx Stock Issued During Period Values Reverse Stock Splits
StockIssuedDuringPeriodValuesReverseStockSplits
0 usd
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
0 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
335246 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-5968869 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
8756680 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
22274740 usd
CY2023Q1 gnpx Stock And Warrants Issued During Period Value New Issues
StockAndWarrantsIssuedDuringPeriodValueNewIssues
4080780 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
21885 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1310230 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9202774 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
18484861 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-5968869 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9202774 usd
CY2024Q1 us-gaap Depreciation
Depreciation
2670 usd
CY2023Q1 us-gaap Depreciation
Depreciation
4016 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
515966 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1332115 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-0 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-34852 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
216623 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1375118 usd
CY2024Q1 gnpx Increase Decrease In Research And Development Supplies
IncreaseDecreaseInResearchAndDevelopmentSupplies
184738 usd
CY2023Q1 gnpx Increase Decrease In Research And Development Supplies
IncreaseDecreaseInResearchAndDevelopmentSupplies
-249542 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
754601 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1769329 usd
CY2024Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-200898 usd
CY2023Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
255601 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5297891 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6932437 usd
CY2024Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1166 usd
CY2023Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
CY2024Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
16988 usd
CY2023Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
19627 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15822 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-19627 usd
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6793199 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4080780 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6793199 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4080780 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1479486 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2871284 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6737629 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20954069 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8217115 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18082785 usd
CY2024Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
7967044 usd
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
6490117 usd
CY2024Q1 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
2532226 usd
CY2023Q4 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
2347488 usd
CY2024Q1 gnpx Number Of Granted Patents
NumberOfGrantedPatents
21 pure
CY2024Q1 gnpx Number Of Pending Patent Applications
NumberOfPendingPatentApplications
24 pure
CY2024Q1 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
64690
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1922586
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1485902
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
346440
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
53695
CY2024Q1 gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
3011751
CY2024Q1 gnpx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
2.26
CY2023Q1 gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
95989
CY2023Q1 gnpx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
44.17
CY2024Q1 gnpx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
0
CY2024Q1 gnpx Class Of Warrant Or Right Cancelled During Period Exercise Price
ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
0
CY2023Q1 gnpx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
960
CY2023Q1 gnpx Class Of Warrant Or Right Cancelled During Period Exercise Price
ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
250
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3358191
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
148724
CY2024Q1 gnpx Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
3352774
CY2023Q1 gnpx Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
142265
CY2024Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3358191
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.93
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y6M
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0452 pure
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8749 pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8314 pure
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
285445
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
438
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
32.4
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2063
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M17D
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M17D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
285883
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
284377
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2063
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
57.23
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
438
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
32.4
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
285445
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
286440
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
251136
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
203500
CY2024Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
37390 usd
CY2023Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
63048 usd

Files In Submission

Name View Source Status
0001437749-24-017061-index-headers.html Edgar Link pending
0001437749-24-017061-index.html Edgar Link pending
0001437749-24-017061.txt Edgar Link pending
0001437749-24-017061-xbrl.zip Edgar Link pending
ex_613980.htm Edgar Link pending
ex_613981.htm Edgar Link pending
ex_613982.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gnpx-20240331.xsd Edgar Link pending
gnpx20240331_10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
gnpx-20240331_def.xml Edgar Link unprocessable
gnpx-20240331_lab.xml Edgar Link unprocessable
gnpx-20240331_pre.xml Edgar Link unprocessable
gnpx20240331_10q_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
gnpx-20240331_cal.xml Edgar Link unprocessable